Argenx delivered $1.3 billion in product net sales for the first quarter, representing 63% year-over-year growth. Revenue expansion is outpacing operating expense growth, driving operating leverage and a 30% operating margin for the quarter as Vyvgart (myasthenia gravis) scales.
Novel FcRn inhibitor Vyvgart is a pipeline in a product, currently approved in myasthenia gravis and CIDP in the US, but it's being evaluated in multiple additional indications.
Vyvgart’s initial average price in myasthenia gravis of $225,000 per year per patient in the US could fall over time, as international launches progress and as competitors reach the market.
|
Metric
|
ARGX
|
CSL
|
JNJ
|
|---|---|---|---|
Price/Earnings (Normalized) | 40.39 | 10.01 | 22.23 |
Price/Book Value | 9.29 | 1.85 | 7.07 |
Price/Sales | 12.77 | 2.19 | 6.03 |
Price/Cash Flow | 53.58 | 9.48 | 19.49 |
|
Metric
|
ARGX
|
CSL
|
JNJ
|
|---|---|---|---|
Quick Ratio | 4.62 | 1.12 | 0.77 |
Current Ratio | 5.23 | 2.57 | 1.03 |
Interest Coverage | 327.44 | 9.23 | 24.09 |
|
Metric
|
ARGX
|
CSL
|
JNJ
|
|---|---|---|---|
Return on Assets (Normalized) | — | — | 13.33% |
Return on Equity (Normalized) | — | — | 32.77% |
Return on Invested Capital (Normalized) | — | — | 20.14% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Jbhmlgbz | Cnhxl | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Njwkvjd | Zytmht | $64B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ndzpkddsz | Tysqj | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Jcbhvnzqjt | Mnlvhs | $24B | |||
| BioNTech SE ADR
BNTX
| Ymxlcbn | Dsd | $23B | |||
| Incyte Corp
INCY
| Swmtppg | Msnm | $22B | |||
| Moderna Inc
MRNA
| Plbfbzlnp | Mhj | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Gzgmybf | Gkns | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Fmvjtfyp | Qsxj | $13B |
/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/ca9ef979-0207-4e37-b392-91618ebc1841.jpg)
United States